Seeking Alpha

RegeneRx announces global development deal for RGN-137; shares up 5%

|About: RegeneRx Biopharmaceut... (RGRX)|By:, SA News Editor

RegeneRx Biopharmaceuticals (OTCQB:RGRX +5%) announces that licensee GtreeBNT has formed a joint venture, Lenus Therapeutics, with YuYang DNA to develop RGN-137 on a global basis for the treatment of epidermolysis bullosa (EB), a rare inherited skin disorder characterized by blisters and erosions.

YuYang will contribute ~$17.8M in cash to the JV while GtreeBNT will contribute the IP rights and development results for RGN-137.

EB-related tickers: KRYS, PRQR, FCSC, MNLO, ABEO

Subscribe for full text news in your inbox